

## **Prof. Dr. Tanja Fehm**

Head of the Dept. Gynecology and Obstetrics  
Moorenstr. 5  
40225 Düsseldorf  
Germany



---

## **CV**

### **PERSONAL**

Date of birth April 23, 1971  
Citizenship German

### **ACADEMIC DEGREES AND FELLOWSHIP**

1993-1998 Medical School University of Erlangen-Nürnberg, Germany  
1998 State licence as a medical doctor  
1998 MD, Dept. Gyn./ OB, University of Erlangen-Nürnberg, Germany  
2001 Adjacent assistant professor, Cancer Immunobiology Center, UT Southwestern, Medical School, Dallas, USA  
2005 Board certified in Obstetrics and Gynecology by the Baden-Wuerttemberg State Chamber of Physicians, Germany  
2005 Postdoctoral thesis ('Habilitation') for Gynecological Oncology 'Phenotyping and genotyping of minimal residual disease in breast cancer'; Mentor: Prof. D. Wallwiener, University Tübingen, Germany  
2012 Board certified in Gynecological Oncology by the Baden-Wuerttemberg State Chamber of Physicians, Germany  
2013 Offer as a full professor / head for the Dept. Gyn / OB in Würzburg and Düsseldorf, Germany  
2013 Full Professur of the Dept. Gyn / OB, University Hospital Düsseldorf, Germany

### **EMPLOYMENT**

1998 – 1999 Resident, Dept. Gyn./OB, University Hospital Erlangen-Nürnberg, Germany  
1999 – 2001 Postdoctoral research fellow at Cancer Immunobiology Center, UT Southwestern, USA (Dr. Vitetta / Dr. Uhr)  
2001 - 2002 Resident, Dept. Gyn./OB, University Hospital Erlangen-Nürnberg, Germany  
2002 - 2005 Resident, Dept. Gyn./OB, University Hospital Tübingen, Germany  
2005 - 2012 Senior physician, Dept. Gyn./OB, University Hospital Tübingen  
Since 2013 Head of the Dept. Gyn./OB, University Hospital Düsseldorf, Germany

### **SELECTED HONOURS / AWARDS / MEMBERSHIP**

2007-13 Spokesman of the Interdisciplinary Center of Gynecological Oncology of the Cancer Comprehensive Center, Tübingen  
Since 2010 Chairman of the Translational Research Group (AGO TRAF0), Germany  
Since 2012 Chairman of the German Society for Gynecological Oncology (AGO e.V), Germany

### **PUBLICATIONS**

peer reviewed articles: > 280, H-index (2017): 38

## **FIVE SELECTED PUBLICATIONS (CLINICAL TRIALS)**

1. Kuehn T,.. **Fehm T et al.**, for the SENTINA Group: Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study; *Lancet Oncol.* 2013;14(7):609-18.
2. Müller V, ..., **Fehm T**; Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. *Breast Cancer Res.* 2012;14(4):R118.
3. von Minckwitz G, ..., **Fehm T et al.**, for the German Breast Group; Arbeitsgemeinschaft. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* 2012;366(4):299-309.
4. Gerber B,...., **Fehm T et al.** for German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. *J Clin Oncol* 2011;29(17):2334-41.
5. **Fehm T et al.** HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. *Breast Cancer Res Treat.* 2010;124(2):403-12.